From Investing.com:

IDEAYA Biosciences has outlined its corporate guidance for 2024, reporting a strong financial position with $511.1 million in cash and marketable securities. It expects to fund operations into 2028 with recent financing activities and a $10 million receivable from GSK. The company also provided updates on its clinical programs.

International site activation and significant patient enrollment for a Phase 2/3 clinical trial of darovasertib and crizotinib combination for the treatment of first-line HLA-A2(-) metastatic uveal melanoma has been achieved. Additional clinical program updates are planned for 2024, including preliminary efficacy results for IDE397 and AMG 193, and ongoing enrollment for IDE161 for HRD solid tumors.

IDEAYA is also advancing its Phase 1 dose escalation for GSK101 and targeting an IND submission for a Werner Helicase Inhibitor Development Candidate, with plans to nominate multiple wholly-owned next-generation development candidates in 2024. The updated corporate presentation reflecting IDEAYA’s 2024 guidance is available on the Investor Relations page of the company’s website.



Read more: IDEAYA Biosciences reveals 2024 guidance and updates By Investing.com